Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TTR | P02766 | 3/20 | 0.44 |
| ▸ | CES1 | P23141 | 1/20 | 0.44 |
| ▸ | BRD4 | O60885 | 2/20 | 0.42 |
| ▸ | MAPK7 | Q13164 | 1/20 | 0.42 |
| ▸ | DRD2 | P14416 | 1/20 | 0.40 |
| ▸ | HTR6 | P50406 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Etazepine SCHEMBL29561205 | 1.00 | TTR (0.44) | TTRCES1BRD4MAPK7DRD2 | |
| SCHEMBL11011176 | 0.84 | CDC25A (0.45) | CES1ALDH1A1 | |
| SCHEMBL10447563 | 0.77 | ACHE (0.46) | TSHRCYP1A2 | |
| SCHEMBL22879456 | 0.73 | TTR (0.50) | TTRCES1DRD2HTR6KDM4E | |
| SCHEMBL13964148 | 0.69 | MEN1 (0.44) | KDM4EALDH1A1HPGDNPC1TP53 | |
| SCHEMBL16127516 | 0.69 | TTR (0.75) | TTRCES1DRD2HTR6KDM4E | |
| SCHEMBL26773614 | 0.69 | PARP1 (0.48) | TTRCES1DRD2HTR6KDM4E | |
| SCHEMBL8506762 | 0.69 | ALDH1A1 (0.41) | CES1DRD2KDM4EALDH1A1HPGD | |
| SCHEMBL3394177 | 0.68 | HSD11B1 (0.39) | BRD4MAPK7KDM4EALDH1A1HPGD | |
| SCHEMBL8907599 | 0.68 | CYP1A2 (0.38) | KDM4EALDH1A1NPC1TP53TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 115 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-120025976-A | Method for differentiating hematopoietic stem/progenitor cells into granulocytes | 苏州血霁生物科技有限公司 | 2025-05-23 | — | — | CN | claimed |
| US-20250163379-A1 | METHOD FOR DIFFERENTIATING HEMATOPOIETIC STEM/PROGENITOR CELLS INTO NK CELLS | HEMACELL BIOTECHNOLOGY INC. (CN) | 2025-05-22 | — | — | US | claimed |
| CN-118786209-A | Method for differentiating hematopoietic stem/progenitor cells into NK cells | 苏州血霁生物科技有限公司 | 2024-10-15 | — | — | CN | claimed |
| WO-2023165503-A1 | METHOD FOR DIFFERENTIATING HEMATOPOIETIC STEM/PROGENITOR CELLS INTO NK CELLS | 苏州血霁生物科技有限公司 | 2023-09-07 | — | — | WO | claimed |
| US-11666547-B2 | Methods for treating cognitive deficits in a subject having schizophrenia, bipolar disorder, or psychiatric depression, and exhibiting cognitive deficits by administering an antagonist of the Na+-K+-2Cl-cation-chloride cotransporter isoform 1 (NKCC1) | NORTHWESTERN UNIVERSITY (US) | 2023-06-06 | — | — | US | claimed |
| US-20200405672-A1 | METHODS FOR TREATING PSYCHIATRIC DISEASES AND DISORDERS AND THE SYMPTOMS THEREOF IN A SUBJECT BY ADMINISTERING AN ANTAGONIST OF THE NA+-K+-2CL- CATION-CHLORIDE COTRANSPORTER ISOFORM 1 (NKCC1) | NORTHWESTERN UNIVERSITY (US) | 2020-12-31 | — | — | US | claimed |
| US-9016221-B2 | Surface topographies for non-toxic bioadhesion control | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2015-04-28 | — | — | US | claimed |
| US-20100226943-A1 | SURFACE TOPOGRAPHIES FOR NON-TOXIC BIOADHESION CONTROL | UNIVERSITY OF FLORIDA (US) | 2010-09-09 | — | — | US | claimed |
| CN-101330905-A | Freeze-drying process and products obtained thereby | SCIDOSE LLC (US) | 2008-12-24 | — | — | CN | claimed |
| EP-1954244-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | Scidose, Llc (US) | 2008-08-13 | — | — | EP | claimed |
| WO-2007061529-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | SCIDOSE LLC. (US) | 2007-05-31 | — | — | WO | claimed |
| US-20070116729-A1 | Lyophilization process and products obtained thereby | SCIDOSE LLC | 2007-05-24 | — | — | US | claimed |
| US-4551451-A | Tricyclic derivatives of 5,6-dihydro-11H-dibenzo (b,e) azepin-6-one having pharmacological activity | A. MENARINI S.A.S. (IT) | 1985-11-05 | — | — | US | claimed |
| WO-2025129358-A1 | STABLE FILM FORMULATIONS FOR HIGH LOADING OF LOW MELTING POINT ACTIVES | INTELGENX CORP. (CA) | 2025-06-26 | — | — | WO | disclosed |
| CN-120025976-A | Method for differentiating hematopoietic stem/progenitor cells into granulocytes | 苏州血霁生物科技有限公司 | 2025-05-23 | — | — | CN | disclosed |
| US-20250163379-A1 | METHOD FOR DIFFERENTIATING HEMATOPOIETIC STEM/PROGENITOR CELLS INTO NK CELLS | HEMACELL BIOTECHNOLOGY INC. (CN) | 2025-05-22 | — | — | US | disclosed |
| US-20020102215-A1 | Diagnostic/therapeutic agents | NYCOMED IMAGING AS | 2002-08-01 | — | — | US | disclosed |
| US-6331289-B1 | ULTRASOUND CONTRAST AGENTS, SUSPENSION IN AQUEOUS CARRIER LIQUID OF A REPORTER COMPRISING GAS-CONTAINING OR GAS-GENERATING MATERIAL, AGENT CAPABLE OF FORMING AT LEAST TWO TYPES OF BINDING PAIRS WITH TARGET; REPORTER BEING CONJUGATED | NYCOMED IMAGING AS (NO) | 2001-12-18 | — | — | US | disclosed |
| US-6264917-B1 | MIXTURE OF GAS FILLED MICROBUBBLES AND RELEASING AGENT | NYCOMED IMAGING AS (NO) | 2001-07-24 | — | — | US | disclosed |
| US-6261537-B1 | TARGETS AND ULTRASOUND DIAGNOSIS OF ACTIVE MATERIALS, AQUEOUS CARRIER LIQUIDS, CARRIERS AND FILM FORMING SURFACTANT PHOSPHATIDES | NYCOMED IMAGING AS (NO) | 2001-07-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11666547-B2 | Methods for treating cognitive deficits in a subject having schizophrenia, bipolar disorder, or psychiatric depression, and exhibiting cognitive deficits by administering an antagonist of the Na+-K+-2Cl-cation-chloride cotransporter isoform 1 (NKCC1) | SLC6A1, SLC6A3, SLC6A13 | TTR 3278/4885CES1 1502/4885BRD4 2216/4885 |
| US-20200405672-A1 | METHODS FOR TREATING PSYCHIATRIC DISEASES AND DISORDERS AND THE SYMPTOMS THEREOF IN A SUBJECT BY ADMINISTERING AN ANTAGONIST OF THE NA+-K+-2CL- CATION-CHLORIDE COTRANSPORTER ISOFORM 1 (NKCC1) | SLC6A1, SLC6A3, SLC6A2 | TTR 3520/4885CES1 1163/4885BRD4 3215/4885 |
| US-20020102215-A1 | Diagnostic/therapeutic agents | BID, FUS, FABP1 | TTR 96/4885CES1 2157/4885BRD4 1147/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.